Collateral for a security interest recorded Jun 30, 2020 (Deerfield Private Design Fund IV, L.P.).
Term ends Jan 15, 2039 · High confidence
20-year base term ends Jan 15, 2039
Held by Exela Pharma Sciences, LLC
Filed Apr 16, 2020 as application 16/850,726 · Granted Feb 9, 2021
Base term, 20 years from filing
Today
2019
2039
Clock starts
Jan 15, 2019
Jan 15, 2019
Term ends
Jan 15, 2039
Jan 15, 2039
Granted
Feb 9, 2021
Feb 9, 2021
base term
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 10,478,453, US 10,583,155, US 10,653,719, US 10,905,713, US 10,933,089, to Jan 15, 2039. The term already ends on or before that date, so the cap shortened nothing.
1 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
19
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 1 of 3 maintenance fees is paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jan 15, 2019, when application 16/248,460, the earliest non-provisional in its chain, was filed (this one was filed Apr 16, 2020) | Jan 15, 2039 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,478,453, US 10,583,155, US 10,653,719, US 10,905,713, US 10,933,089) | resolves to Jan 15, 2039, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jan 15, 2039 | High confidence |
This family
| US 10,478,453 | In force Jan 2039 | Jan 2039 |
| US 10,583,155 | In force Jan 2039 | Jan 2039 |
| US 10,933,089 | In force Jan 2039 | Jan 2039 |
| US 10,905,713 | In force Jan 2039 | Jan 2039 |
| US 10,653,719 | In force Jan 2039 | Jan 2039 |
| US 10,905,714 | In force Jan 2039 | Jan 2039 |
| US 10,912,795 | this patent Jan 2039 | Jan 2039 |
| US 10,918,662 | In force Jan 2039 | Jan 2039 |
8 of 19 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jun 18, 2020 Reel 52979, frame 908 | Maloney, John; Koganti, Aruna; Koneru, Phanesh | Exela Pharma Sciences, LLC | Assignment of Assignor's Interest |
| Jun 30, 2020 Reel 53083, frame 783 | Exela Pharma Sciences, LLC | Deerfield Private Design Fund IV, L.P. | Security Interest |
| Mar 25, 2021 Reel 55749, frame 134 | Exela Pharma Sciences, LLC | Deerfield Private Design Fund IV, L.P. | Corrective Assignment to Correct the Property Number 16772641 and to Remove 10653791 Previously Recorded at Reel: 053083 Frame: 0783. Assignor(S) Hereby Confirms the Security Interest. |
| Jun 30, 2021 Reel 56722, frame 250 | Exela Holdings, Inc.; Exela Pharma Sciences, LLC; Exela Pharmsci, Inc.; Exela Sterile Medicines LLC; Exela Sterile Products LLC; Exela Sterile Equipment, LLC; Exela Advanced Strategies LLC; Agelex, LLC; Exela Health Systems, LLC; Exela Initiatives, LLC; Exela Innovations, LLC | Live Oak Banking Company | Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Jan 2039
Term ends Jan 15, 2039. Maintenance fees still fall due before then
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 10,478,453, US 10,583,155, US 10,653,719, US 10,905,713, US 10,933,089, ends no earlier than this term, so it caps nothing.
Citations
11
later US patents cite this one
That is top 25% of utility patents granted in 2021 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.